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Abstract
According to the current dogma, cholesteryl ester transfer protein (CETP) decreases high-density lipoprotein (HDL)-
cholesterol (C) and increases low-density lipoprotein (LDL)-C. However, detailed insight into the effects of CETP on
lipoprotein subclasses is lacking. Therefore, we used a Mendelian randomization approach based on a genetic score for
serum CETP concentration (rs247616, rs12720922 and rs1968905) to estimate causal effects per unit (µg/mL) increase in
CETP on 159 standardized metabolic biomarkers, primarily lipoprotein subclasses. Metabolic biomarkers were measured by
nuclear magnetic resonance (NMR) in 5672 participants of the Netherlands Epidemiology of Obesity (NEO) study. Higher
CETP concentrations were associated with less large HDL (largest effect XL-HDL-C, P= 6 × 10–22) and more small VLDL
components (largest effect S-VLDL cholesteryl esters, P= 6 × 10–6). No causal effects were observed with LDL subclasses.
All these effects were replicated in an independent cohort from European ancestry (MAGNETIC NMR GWAS; n ~20,000).
Additionally, we assessed observational associations between ELISA-measured CETP concentration and metabolic
measures. In contrast to results from Mendelian randomization, observationally, CETP concentration predominantly
associated with more VLDL, IDL and LDL components. Our results show that CETP is an important causal determinant of
HDL and VLDL concentration and composition, which may imply that the CETP inhibitor anacetrapib decreased
cardiovascular disease risk through speciﬁc reduction of small VLDL rather than LDL. The contrast between genetic and
observational associations might be explained by a high capacity of VLDL, IDL and LDL subclasses to carry CETP, thereby
concealing causal effects on HDL.
Introduction
Cholesteryl ester transfer protein (CETP) is able to transfer
cholesteryl esters from high-density lipoproteins (HDL) to
apolipoprotein B (ApoB) containing triglyceride-rich
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lipoproteins, mainly very-low-density lipoproteins (VLDL).
In exchange, triglycerides are transferred from VLDL to
triglyceride-poor particles, which are both HDL and low-
density lipoprotein (LDL) [1]. As such, CETP facilitates an
atherogenic lipoprotein proﬁle, as has been extensively
studied in both humans and in mice transgenic for human
CETP [2, 3].
Despite the promising results of preclinical studies [4, 5],
the clinical trials with the initial CETP inhibitors, torce-
trapib, dalcetrapib and evacetrapib, were terminated: tor-
cetrapib had off-target effects on blood pressure and caused
an increase in cardiovascular events [6], and both dalce-
trapib and evacetrapib lacked efﬁcacy in reducing cardio-
vascular events on top of statin therapy [7, 8]. All these
CETP inhibitors caused a large increase in HDL-cholesterol
(C), accompanied by a modest or no decrease in non-HDL-
C. Although a high HDL-C concentration was previously
proposed to decrease the risk of cardiovascular disease
(CVD) based on observational studies [9], Mendelian ran-
domization showed that higher HDL-C concentrations do
not lower the risk of myocardial infarction [10–13].
Although HDL functionality may still inﬂuence CVD risk,
this implies that at least the association between HDL-C and
CVD is not causal. This may provide one of the possible
explanations for the lack of efﬁcacy of the three initial
CETP inhibitors [6–8].
Interestingly, the fourth clinical trial with the CETP
inhibitor anacetrapib (REVEAL) did meet its primary end-
point by showing a 9% relative risk reduction in major
coronary events [14]. The reduction in coronary events by
anacetrapib, albeit limited, was attributed to a reduction in
LDL-C and a corresponding reduction in ApoB-containing
lipoprotein particles [14, 15]. However, the speciﬁc lipo-
protein subclasses affected by CETP have not been deter-
mined yet. Speciﬁc lipoprotein fractions have previously
been associated with increased CVD risk [16], and more in-
depth insight in the causal effects of CETP on the circu-
lating lipoprotein proﬁle may therefore assist in under-
standing CETP inhibitor trial outcomes.
We recently performed a genome-wide association study
(GWAS) on serum CETP concentration in the Netherlands
Epidemiology of Obesity (NEO) study, and showed that
CETP concentration has a strong genetic component [17].
Notably, three independent single-nucleotide polymorph-
isms (SNPs), all mapped to the CETP gene, together
explained 16.4% of the total variation in serum CETP
concentration, and were associated with a non-statistically
signiﬁcant odds ratio of 1.08 (0.94–1.23) for coronary artery
disease risk [17]. With the use of these SNPs as genetic
instruments in Mendelian randomization, the causal effects
of circulating CETP on lipoprotein subclasses can be
determined to provide more insight into CETP biology.
Mendelian randomization assumes random assortment of
alleles across a population, and is increasingly used to
ascertain causality between genetic exposures and outcomes
in the absence of confounding [18, 19]. Furthermore,
potential reverse causation can be ruled out given that an
outcome cannot inﬂuence genetic information.
In the present study, we thus aimed to assess the causal
effects of CETP concentration on 159 circulating metabolic
measures, primarily lipoprotein subclasses, using a
Mendelian randomization approach in a cohort of the
Dutch general population [20]. We also compared the
causal effect estimates with observational associations
between serum CETP concentration and these measures of
lipid metabolism.
Materials and methods
Study design and populations
The present study is embedded in the NEO study, a
population-based prospective cohort study of men and
women aged 45 to 65 years. For the present study, we
excluded participants with missing data on serum CETP
concentration, metabolic proﬁling or genotype. Therefore,
the present study population consists of 5672 individuals.
The NEO study was approved by the medical ethics com-
mittee of the Leiden University Medical Center (LUMC),
and all participants gave their written informed consent. The
study conformed to the principles outlined in the Declara-
tion of Helsinki. Detailed information about the study
design and data collection has been described elsewhere
[21].
Genotyping and imputation
DNA was isolated from venous blood samples. Genotyping
was performed in participants from European ancestry,
using the Illumina HumanCoreExome-24 BeadChip (Illu-
mina Inc., San Diego, California, USA). Subsequently,
genotypes were imputed to the 1000 Genome Project
reference panel (v3 2011) [22] using IMPUTE (v2.2) soft-
ware [23]. From the whole-genome data, we extracted the
three independent genetic variants that have been previously
identiﬁed in relationship to CETP concentration in the
NEO study population, notably rs247616 (chr16:
g.56989590C>T; directly genotyped; coding allele (C) fre-
quency 0.67), rs12720922 (chr16:g.57000885G>A; impu-
tation quality 0.98; coding allele frequency (A) 0.17) and
rs1968905 (chr16:g.57010948T>G; imputation quality
0.85; coding allele frequency (G) 0.82) [17]. The CETP-
increasing alleles are rs247616-C, rs12720922-A and
rs1968905-G. Based on these three polymorphisms, we
calculated a weighted genetic score per participant. The
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genetic score was constructed as the sum of the number of
CETP-increasing alleles weighted by their effect size on
CETP concentration, as previously described [17].
Serum CETP concentration and routine-lipid proﬁle
After centrifugation, aliquots of serum were stored at –80 °
C. From 11 April until 16 July 2014, CETP concentrations
were measured with enzyme-linked immune sorbent assay
(ELISA) kits according to the manufacturer’s instructions
(DAIICHI CETP ELISA, Alpco, Salem, USA; coefﬁcient
of variation (CV) 11.7%) in serum that had undergone one
previous freeze–thaw cycle. Fasting serum total cholesterol
and triglycerides concentrations were measured with enzy-
matic colorimetric assays (Roche Modular P800 Analyzer,
Roche Diagnostics, Mannheim, Germany) and fasting
serum HDL-C concentrations with third-generation homo-
genous HDL-C methods (Roche Modular P800 Analyzer,
Roche Diagnostics, Mannheim, Germany). Fasting LDL-C
concentrations were calculated using the Friedewald equa-
tion [24].
NMR-based metabolic biomarker proﬁling
A high-throughput proton nuclear magnetic resonance
(NMR) metabolomics platform [20] (Nightingale Health
Ltd., Helsinki, Finland) was used to quantify 159 lipid and
metabolite measures. The NMR spectroscopy was con-
ducted at the Medical Research Council Integrative Epide-
miology Unit (MRC IEU) at the University of Bristol,
Bristol, UK, and processed by Nightingale’s biomarker
quantiﬁcation algorithms (version 2014). This method
provides quantiﬁcation of lipoprotein subclass proﬁling
with lipid concentrations within 14 lipoprotein subclasses.
The 14 subclass sizes were deﬁned as follows: extremely
large VLDL with particle diameters from 75 nm upwards
and a possible contribution of chylomicrons, ﬁve VLDL
subclasses (average particle diameters of 64.0 nm, 53.6 nm,
44.5 nm, 36.8 nm and 31.3 nm), IDL (28.6 nm), three LDL
subclasses (25.5 nm, 23.0 nm and 18.7 nm) and four HDL
subclasses (14.3 nm, 12.1 nm, 10.9 nm and 8.7 nm). Within
the lipoprotein subclasses the following components were
quantiﬁed: total cholesterol, total lipids, phospholipids, free
cholesterol, cholesteryl esters and triglycerides. The mean
size for VLDL, LDL and HDL particles was calculated by
weighting the corresponding subclass diameters with their
particle concentrations. Furthermore, 58 metabolic mea-
sures were determined that belong to classes of apolipo-
proteins, cholesterol, fatty acids, glycerides, phospholipids,
amino acids, ﬂuid balance, glycolysis-related metabolites,
inﬂammation and ketone bodies. Details of the experi-
mentation and applications of the NMR metabolomics
platform have been described previously [20], as well as
CVs for the metabolic biomarkers [25]. A full list of the
measured biomarkers is included in Supplementary Table 1.
Statistical analyses
For all analyses, metabolic measures were natural-log
transformed to obtain normal distributions. For compar-
ison of the strengths of the associations between the dif-
ferent metabolic measures, standardized z-scores were
composed. Consequently, the outcome variable of all ana-
lyses was the natural-log transformed SD difference in
metabolic measure. When the concentration of a metabolic
measure for an individual was below the detection limit, a
value of half of the minimum concentration of that meta-
bolic measure in the total population was imputed.
First, we performed a Mendelian randomization analysis
to determine the causal associations between serum CETP
concentration and the 159 metabolic measures. The genetic
score was used as determinant in a linear regression analysis
to assess the effect of a one unit (µg/mL) increase in serum
CETP concentration on the metabolic measures. Second,
the observational associations between serum CETP con-
centration and the 159 metabolic measures were determined
with linear regression analyses. Participants with a serum
CETP concentration beyond four SD from the mean were
excluded (n= 1). All linear regression analyses were
adjusted for age and sex. Since we previously observed that
serum CETP concentration is not associated with possible
confounding factors such as measures of body fat [26],
markers of liver inﬂammation and function [27] and hepatic
triglyceride content (unpublished data), we did not adjust
for any additional factors apart from age and sex. Beta
coefﬁcients, SE and P values from linear regression ana-
lyses were reported. In addition, a linear regression analysis
adjusted for age and sex was performed to determine the
associations of serum CETP concentration with routinely
measured HDL-C concentration and calculated Friedewald
LDL-C concentration.
A power analysis was conducted to assess the minimally
required effect size in the NEO study population. For
this, we used the online calculator available on: http://
cnsgenomics.com/shiny/mRnd/. [26] Considering the
number of independent metabolites (alpha= 0.00134) and
a power of 0.80, the power calculation showed that we
were able to observe associations with an effect size of
0.132 SD in the NEO study population.
The metabolic biomarkers used for the present study are
correlated with each other, and therefore conventional cor-
rection for multiple testing (e.g., Bonferroni) is too strin-
gent. To obtain the number of independent metabolic
biomarkers, we used the method as described by Li and Ji
[27], which takes the correlation between the different
metabolic biomarkers into account. Based on this method,
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we found 37 independent metabolic markers. For this
reason, associations were considered to be statistically
signiﬁcant in case the P value was below 0.00134 (i.e.,
0.05/37).
An important assumption of Mendelian randomization
is that the genotype is only associated with the outcome
via the exposure. This assumption can be violated when
pleiotropy is present, which means that the genotype
may be associated with the outcome via phenotypes
other than the exposure. To gain insight into the possible
pleiotropic effects of the individual variants, we performed
an instrumental variable analysis for each of the three
genetic variants separately. This analysis was performed
by dividing the per-allele effect of an individual SNP for
each metabolite by the per-allele effect of this SNP on
CETP concentration. The per-allele effects of the genetic
instruments on CETP concentration were 0.32 µg/mL for
rs247616, 0.35 µg/mL for rs12720922 and 0.12 µg/mL for
rs1968905, as we showed previously [17]. These ratios
deﬁne the effects of the SNPs on the metabolic measure
per one unit (1 µg/mL) increase in CETP concentration,
thereby allowing for direct comparison of the effects of
the three different SNPs on the lipoprotein proﬁle. In case
no pleiotropy is present, it is expected that ratios are com-
parable between the different SNPs, whereas observed
differences in effects between the SNPs indicate possible
pleiotropic effects. In addition, we checked whether the
genetic variants were associated with potential confounders
of the associations between CETP concentration and
metabolite measures, i.e., alanine transaminase, aspartate
transaminase, systolic blood pressure, diastolic blood pres-
sure, body mass index (BMI), body fat percentage and C-
reactive protein.
All results were based on analyses weighted towards the
reference BMI distribution of the general Dutch population,
and therefore apply to a population-based study without
oversampling of individuals with overweight or obesity
(see Supplementary Materials and Methods). Analyses were
performed using STATA Statistical Software version 12.0
(Statacorp, College Station, Texas, USA) and R version
3.4.0 (The R Project, https://www.r-project.org/). Figures
were designed with Python version 2.7.6 (Python Software
Foundation, https://www.python.org/).
Replication
We aimed to replicate the ﬁndings from the Mendelian
randomization analyses in the NEO study in an independent
population. For that purpose, we used publically available
summary statistics from the MAGNETIC NMR GWAS
dataset [25], which comprises the additive (per-allele) beta
coefﬁcients with accompanying standard errors of the
associations between genome-wide SNPs and 123
metabolic measures, of which 111 overlapped with the 159
metabolic measures that were quantiﬁed in the NEO study.
This GWAS meta-analysis included data of ~20,000 indi-
viduals from 14 datasets that were derived from cohorts of
European ancestry. The 123 metabolic measures were
quantiﬁed by a prior version of the same high-throughput
proton NMR metabolomics platform [20] (Nightingale
Health Ltd., Helsinki, Finland) as used in the NEO study. In
these metabolomics data, 22 principal components were
identiﬁed [25], and therefore associations were considered
to be statistically signiﬁcant in case the P value was below
0.00227 (i.e., 0.05/22).
For the Mendelian randomization analyses, we sum-
marized the genetically determined effect of 1 µg/mL CETP
using the same genetic instruments (i.e., rs247616,
rs12720922 and rs1968905) as in the analysis of the NEO
study population to estimate the causal effect of CETP
concentration on the metabolic measures. We weighted this
combined effect estimate of the CETP SNPs on the meta-
bolic measures by the inverse of the variance for each
individual additive (per-allele) effect on the metabolic
measures, and incorporated the individuals additive effects
of the genetic instruments on CETP concentration. Addi-
tionally, we determined the correlation (R2) between the
effect estimates from the NEO study and the MAGNETIC
NMR GWAS dataset. A strong correlation indicates
high consistency in the overall association proﬁle of




Characteristics of the total study population are summarized
in Table 1. The mean (SD) age was 56 (6) years. Mean
(SD) concentration of CETP was 2.47 (0.65) µg/mL, of
LDL-C 3.56 (0.96) mmol/L and of and HDL-C 1.57 (0.46)
mmol/L.
Causally, CETP is negatively associated with large
HDL components and positively associated with
small VLDL components
Figure 1 and Supplementary Table 2 show the results from
the Mendelian randomization analyses of CETP and 159
circulating metabolic measures. The association with the
CETP genetic score was statistically signiﬁcant for 46
metabolic measures (P < 0.00134).
CETP concentration most strongly affected very large,
large and medium HDL subclasses. With a 1 µg/mL
increase in CETP, all components of these lipoprotein
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subclasses decreased. The only exception was the trigly-
ceride content in medium HDL, for which the effect size
was positive (effect (SE): 0.272 (0.055), P= 9 × 10–7). In
line with this, triglycerides in small HDL also showed a
positive beta (effect (SE): 0.293 (0.055), P= 1 × 10–9). In
accordance with the decrease in larger HDL subclasses with
higher CETP concentration, higher CETP was also asso-
ciated with a smaller HDL diameter and less ApoA1.
Overall, the largest effects were found for cholesterol in
very large HDL (effect (SE): –0.517 (0.053), P= 6 × 10–22).
When comparing the lipoprotein components within the
very large, large and medium HDL subclasses, the choles-
terol components, i.e., cholesteryl esters and free choles-
terol, consistently showed the largest effect sizes.
Remarkably, CETP concentration did not associate with
any of the LDL subclass components, while a higher CETP
concentration associated with more small and very small
VLDL. The largest increasing effect was found for cho-
lesteryl esters in small VLDL (effect (SE): 0.276 (0.061), P
= 6 × 10–6). There were no pronounced differences in the
effect sizes between the various components within VLDL
subclasses.
The results from the independent replication dataset can
be found in Supplementary Figure 1 and Supplementary
Table 2. The pattern of lipidomic associations was con-
sistent in the replication dataset (Fig. 2), also when eval-
uated for the three SNPs of the genetic score separately
(Supplementary Figures 2–4). To get insight into the pos-
sible pleiotropic effects, the results of the instrumental
variable analyses are shown in Supplementary Figure 5.
Notably, effects of the rs1968905 variant on HDL meta-
bolites deviated from those of the two other SNPs, which
may indicate pleiotropy. The genetic score was not asso-
ciated with possible confounders of the association between
CETP concentration and metabolic measures (Supplemen-
tary Table 3).
Observationally, CETP concentration is
predominantly positively associated with very small
VLDL, IDL and LDL components
Figure 3 and Supplementary Table 4 show the observational
associations between measured serum CETP concentration
and the 159 circulating metabolic measures. A higher
CETP concentration was positively associated with all
VLDL, IDL and LDL subclasses, of which very small
VLDL, IDL and all three LDL subclasses showed the
strongest associations. This is in line with the associations
between serum CETP concentration and the routine-
lipid measurements (age- and sex-adjusted), since
we observed a large effect on Friedewald LDL-C con-
centration per unit increase in CETP concentration
(effect size 0.46 mmol/L; 95% conﬁdence interval (CI)
0.40–0.52), compared to the relatively small effect on HDL-
C concentration (effect size –0.05 mmol/L; 95% CI –0.07
to –0.02). Crude associations are shown in Supplementary
Figure 6.
The largest effect sizes for observational associations
were found for free cholesterol in very small VLDL
(effect (SE): 0.476 (0.030), P= 2 × 10–55) and phospholi-
pids in very small VLDL (effect (SE): 0.472 (0.030),
P= 2 × 10–56). When comparing the lipoprotein compo-
nents (i.e., cholesteryl esters, free cholesterol, phospholipids
and triglycerides) within the very small VLDL, IDL and
LDL subclasses, the shell components, i.e., phospholipids
and free cholesterol, quite consistently (apart from small
LDL) showed the largest effect sizes, whereas the effect for
the core component triglycerides was, consistently, the
smallest. Concerning the HDL subclasses, higher CETP
concentration was associated with a higher concentration of
small HDL particles, whereas no associations were found
with concentrations of very large, large and medium HDL
particles.
Overall, observational and genetic associations were
hardly consistent. Only for VLDL effect directions were
similar (i.e., positive) between genetic and observational
associations.
Table 1 Characteristics of the total study population from the
Netherlands Epidemiology of Obesity (NEO) study
Characteristics
Age (year) 56 (6)
Women (%) 56
Educational level (% higha) 47
Body mass index (kg/m2) 26.3 (4.4)
Tobacco smoking (% current and former smokers) 62
Cardiovascular disease (%) 5
Lipid-lowering drug users (%) 11
Fasting serum concentrations
CETP (µg/mL) 2.47 (0.65)
Total cholesterol (mmol/L) 5.70 (1.05)
LDL-cholesterol (mmol/L) 3.56 (0.96)
HDL-cholesterol (mmol/L) 1.57 (0.46)
Triglycerides (mmol/L) 1.23 (0.85)
N= 5672 (missing data: n= 4 for ethnicity, n = 56 for educational
level, n= 4 for smoking, n= 21 for cardiovascular disease, n= 8 for
total cholesterol concentration, n = 10 for LDL-cholesterol concentra-
tion, n = 9 for HDL-cholesterol concentration and n= 9 for
triglyceride concentration). Results are based on analyses weighted
towards the reference BMI distribution of the general Dutch
population, and presented as mean (SD) or percentage
CETP cholesteryl ester transfer protein, HDL high-density lipoprotein,
LDL low-density lipoprotein
aHigh educational level: higher secondary education (according to
Dutch educational system), higher vocational education, university,
PhD
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Discussion
In this study, we determined the causal effects of serum
CETP on the circulating lipoprotein proﬁle, and contrasted
the results to observational associations. We used three
recently identiﬁed CETP SNPs [17] (i.e., rs247616,
rs12720922 and rs1968905) that together explain 16.4% of
the total variation in serum CETP concentration as genetic
instruments in Mendelian randomization to enable infer-
ences of causality on 159 circulating metabolic measures.
Higher circulating CETP concentrations were causally most
strongly associated with lower concentrations of very large,
large and medium-sized HDL components, a smaller overall
HDL diameter, less ApoA1 and more small VLDL com-
ponents, while there was no association with LDL compo-
nents. In contrast, observationally, measured serum CETP
concentration predominantly associated with more VLDL,
IDL and LDL components.
Fig. 1 Causal associations
between CETP concentration
and 159 circulating metabolic
measures, which were assessed
with a Mendelian randomization
approach based on a CETP
genetic score, in the Netherlands
Epidemiology of Obesity (NEO)
study (n= 5672). The genetic
score for Mendelian
randomization is based on the
CETP SNPs rs247616,
rs12720922 and rs1968905, as
previously determined with a
genome-wide association study
on serum CETP concentration
[17]. Bar heights represent the
magnitude of the beta-
coefﬁcient from linear
regression, which is expressed
as the SD difference in
metabolic measure per 1 µg/mL
increase in CETP concentration.
Red bars indicate positive betas
and blue bars indicate negative
betas. The transparency of the
bars indicates the level of
statistical signiﬁcance. A P
value < 0.00134 is regarded
statistically signiﬁcant, as
represented by the black dots.
Full names and descriptions of
metabolic measures are listed in
Supplementary Table 1. Results
are based on analyses weighted
towards the reference BMI
distribution of the general Dutch
population
Fig. 2 The effects sizes of the causal associations between CETP
concentration and metabolic measures in the Netherlands Epidemiol-
ogy of Obesity (NEO) study are strongly replicated in independent
European populations (MAGNETIC NMR GWAS dataset), as shown
by the high correlation between the beta-coefﬁcients from both
cohorts. Beta-coefﬁcient from linear regression are expressed as the
SD difference in metabolic measure per 1 µg/mL increase in CETP
concentration. NEO study results are based on analyses weighted
towards the reference BMI distribution of the general Dutch
population
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Based on the principle of Mendelian randomization,
the association between the CETP genetic score and
lipoprotein subclasses can be interpreted as causal, thereby
providing insight into human CETP biology [28, 29]. The
results from our Mendelian randomization analyses are
fully consistent with the mechanism by which CETP
transfers cholesteryl esters from HDL towards ApoB-
containing triglyceride-rich lipoproteins, mainly VLDL,
and mediates the transfer of triglycerides from VLDL
towards triglyceride-poor particles, such as HDL [1, 30, 31].
CETP accelerates the clearance of HDL from blood
by enrichment of HDL with triglycerides, which makes
this HDL a preferred substrate for hepatic triglyceride
lipase [32]. Catabolism of triglyceride-rich HDL by
hepatic triglyceride lipase leads to the formation of very
small remnant HDL that is cleared by the liver and kidneys
[32–37]. Indeed, in the present study, the CETP genetic
score was associated with a smaller HDL diameter, and
with a higher triglyceride content speciﬁcally in the medium
and small HDL particles. Also, our results show that
the CETP mainly affects the HDL pool, which is in
accordance with the lipoprotein proﬁle observed in CETP-
deﬁcient individuals, who have markedly increased
amounts of large HDL particles [38–40], while effects
on LDL and VLDL subclasses are less pronounced [40].
Our results are also in line with previously performed
genetic association studies that identiﬁed CETP loci as
strong determinants of HDL measures [41–43], without
having effects on LDL-C [42].
Importantly, since effects of the rs1968905 variant on
HDL metabolites deviated from those of the two other
SNPs, it is plausible that pleiotropy plays in role in the
effects of the rs1968905 variant on HDL metabolites, as we
suggested before [17]. Thus, possibly the rs1968905 variant
is associated with the HDL metabolites via phenotypes
other than CETP concentration. Therefore, the HDL-related
Fig. 3 Observational
associations between serum
CETP concentration and 159
circulating metabolic measures,
in the Netherlands
Epidemiology of Obesity (NEO)
study (n= 5672). Bar heights
represent the magnitude of the
beta-coefﬁcient from linear
regression, which is expressed
as the SD difference in
metabolic measure per 1 µg/mL
increase in serum CETP. Red
bars indicate positive betas and
blue bars indicate negative betas.
The transparency of the bars
indicates the level of statistical
signiﬁcance. A P value <
0.00134 is regarded statistically
signiﬁcant, as represented by the
black dots. Full names and
descriptions of metabolic
measures are listed in
Supplementary Table 1. Results
are based on analyses weighted
towards the reference BMI
distribution of the general Dutch
population
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results for this variant speciﬁcally should be interpreted
with caution, when making statements about direct effects
of CETP.
Our results may also shed light on the mechanisms that
underlie the effectiveness of CETP inhibition [28, 29].
Therefore, it is highly interesting to discuss the present
study results in light of the results from the REVEAL
trial with the CETP inhibitor anacetrapib, which showed
a reduction in major coronary events [44]. Our ﬁndings
implicate that CETP inhibition causes a relatively large
increase in HDL components, which is predominantly
caused by an increase in large and medium-sized
HDL particles, in addition to a more modest reduction
in VLDL components, which is mainly caused by a
decrease in small and extra small VLDL particles. Of
note, LDL concentration and composition were not affected
by CETP, which was unexpected based on the current
dogma that CETP increases LDL-C. However, it should
be realized that LDL-C is generally not measured directly
but calculated from the Friedewald formula [24],
which may well misclassify cholesterol contained within
small VLDL subclasses as LDL-C. It was previously
reported that small and very small VLDL particle con-
centrations (reﬂecting triglyceride-rich lipoprotein rem-
nants) and cholesterol in VLDL (reﬂecting remnant
cholesterol) are among the lipoprotein components that
most strongly associate with an increased CVD risk [16, 45,
46]. Thus, although we cannot rule out that CETP inhibition
may beneﬁcially affect HDL functionality and reduce
CVD, the positive outcome of the latest CETP inhibition
trial with anacetrapib [14] may well be explained by a
reduction of small VLDL particles.
We compared the genetic associations with non-causal
observational associations between serum CETP con-
centration measured with ELISA and all 159 metabolic
measures. Observationally, associations were markedly
different, as CETP concentration was predominantly posi-
tively associated with very small VLDL, IDL and LDL
components, whereas no negative associations with HDL
components were observed. This indicates that confounding
factors conceal the true causal association. Although we
showed previously that CETP concentration is strongly
genetically determined [17], still the majority of the total
variation in CETP concentration between individuals is
caused by unknown factors. It should be realized that, just
like apolipoproteins, CETP is an amphiphilic protein that
binds to lipid surfaces of lipoproteins. It is thus conceivable
that the capacity of lipoproteins to carry CETP is one of the
factors that may explain the marked differences between the
genetic and observational associations.
We propose that the contrast between genetic and
observational associations may be explained by the higher
capacity of VLDL, IDL and LDL subclasses to carry CETP,
thereby concealing causal associations with HDL. The
distribution of CETP over circulating lipoproteins has been
extensively studied in the past, however, with diverging
conclusions. The earliest studies proposed that CETP is
predominantly bound to HDL particles [47–49]. However,
thereafter, it was shown that CETP also avidly binds to
LDL and VLDL, although the binding to these particles
might be more labile [50]. It should be noted that the dis-
tribution of CETP over the various lipoprotein subclasses
has commonly been determined after separating lipopro-
teins with ultracentrifugation, thereby presumably disrupt-
ing the binding within the least stable CETP-lipoprotein
complexes. In addition, storage of plasma samples may also
alter the distribution of CETP over lipoproteins. Indeed,
marked effects of storage on the lipoprotein distribution
have been observed for ApoC3 and ApoE following fast
protein liquid chromatography [51]. Results from previous
studies may therefore not accurately represent the distribu-
tion of CETP over lipoproteins within the circulation.
Remarkably, in the present study, observational serum
CETP concentration showed the strongest associations with
the shell components (i.e., phospholipids and free choles-
terol) of very small VLDL, IDL and LDL subclasses. This
may indicate that CETP is mostly carried on the surface of
these particles in the circulation, although future studies are
needed to substantiate this hypothesis.
The main strength of the present study is the use of a
strong genetic instrument in Mendelian randomization to
draw conclusions on the causal effects of CETP con-
centration on the circulating lipoprotein proﬁle. In addition,
sufﬁcient statistical power for the analyses was provided, as
we had genetic data and NMR-metabolomic proﬁles avail-
able of 5672 individuals, which we were able to replicate in
an independent dataset (n ~20,000). However, the study
populations were from European ancestry and results may
therefore not be generalizable to other populations. Inter-
estingly, a recent study in a Chinese population, which used
a different CETP genetic score (i.e., rs3764261, rs1800775,
rs708272, rs9939224 and rs2303790), showed comparable
results [52]. This indicates consistency of the results among
different ancestries.
Based on Mendelian randomization, we conclude that
CETP is an important determinant of HDL concentration
and composition, without affecting LDL concentration and
composition. Our ﬁnding challenges the current dogma that
CETP increases LDL-C, mainly based on indirect LDL-C
estimation using the Friedewald formula [24]. Instead, by
directly assessing the lipoprotein proﬁle by NMR, we now
show that CETP speciﬁcally increases small VLDL frac-
tions that likely represent VLDL remnants. Therefore, we
speculate that the CETP inhibitor anacetrapib attenuated
cardiovascular disease risk through speciﬁc reduction of
remnant cholesterol rather than LDL-C.
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